Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

BACKGROUND: This study explored the efficacy of lenalidomide plus rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) including cases of secondary central nervous system (CNS) involvement and transformed follicular lymphoma (FL) in real-world context because of a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Manag Res
Hlavní autoři: Lee, Yong-Pyo, Hong, Jung Yong, Yoon, Sang Eun, Cho, Junhun, Shim, Joon-Ho, Bang, Yeonghak, Kim, Won Seog, Kim, Seok Jin
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168964/
https://ncbi.nlm.nih.gov/pubmed/34093038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S309092
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky